Need for repeated dosing or sustained release formulations overcome degradation
By donating acetyl groups to NF-B p65/RelA, ALC enhances transcription of the GRM2 gene encoding metabotropic glutamate 2 (mGlu2) receptors.[11][12] This upregulation of mGlu2 receptors at nerve terminals produces analgesia and prevents spinal sensitization, with effects that persist for weeks to months after discontinuationa feature distinguishing ALC from conventional analgesics.[11] In experimental models, ALC blocks wind-up and long-term potentiation in dorsal horn neurons, key processes underlying central sensitization.[11] The analgesic effects of ALC outlast the end of treatment in mouse models of chronic inflammatory and neuropathic pain, with effects persisting 37 days after drug withdrawal compared to 7-15 days for pregabalin or amitriptyline.[11] Clinical evidence in fibromyalgia (a prototypical central sensitization condition) supports this mechanism, with multiple RCTs demonstrating benefit.[11] Combination Strategies for Central Sensitization: ALC 1,500-2,000 mg/day + PEA 1,200 mg/day (demonstrated synergy in fibromyalgia)[3] + Magnesium 400-600 mg/day (complementary glutamate modulation) + Low-dose naltrexone (complementary anti-sensitization mechanisms) 2
[DOI] [PMC free article] [PubMed] [Google Scholar] 78.Smoday I.M., Petrovic I., Kalogjera L., Vranes H., Zizek H., Krezic I., Gojkovic S., Skorak I., Hriberski K., Brizic I., et al
10.1165/rcmb.2004-0058OC Am
Mir Najib Ullah SN, Afzal O, Altamimi ASA, Ather H, Sultana S, Almalki WH et al (2023) Nanomedicine in the management of Alzheimers disease: state-of-the-art
Hypertension 62 , 957965 (2013)
)
